Although other biomarkers for risk stratification such as apolipoprotein B (apoB) may be superior [2,3], the accurate measurement of LDL cholesterol (LDL-C) at both low and high levels is still important when following current guidelines for the clinical management of patients for the prevention of atherosclerotic cardiovascular disease (ASCVD) risk [4]. This evidence concerns the gene APOB and atherosclerosis.